ARWR insider files Form 144/A to sell 100,000 shares

ARWR submitted an amended Form 144/A reporting a proposed resale of 100,000 common shares by Daniel Apel.

Rhea-AI Filing Summary

ARWR submitted an amended Form 144/A reporting a proposed resale of 100,000 common shares by Daniel Apel. The filing lists the shares as issued for compensation (a bonus) with an original grant date of 04/15/2025 and the Form 144/A date of 04/22/2026.

Insights

Corporate Governance Analyst

Notice of a planned insider resale of compensation shares.

The excerpt shows a Form 144/A amendment that lists 100,000 common shares tied to a bonus awarded on 04/15/2025

Timing and pricing details for the resale are not provided in the excerpt; subsequent filings or broker execution notices would specify the sale mechanics.

Insider Transactions Specialist

Form 144/A records a director-associated resale notification.

The filing names Daniel Apel as the holder and classifies the shares under compensation. Form 144/A is a regulatory notice of intent to sell; it does not by itself confirm completed sales.

Cash‑flow treatment and broker methods are not disclosed in the provided excerpt.

Key Figures

Filed shares: 100,000 shares Grant date: 04/15/2025 Form 144/A date: 04/22/2026

3 metrics

Filed shares 100,000 shares listed on Form 144/A as proposed resale

Grant date 04/15/2025 original bonus grant date shown in filing

Form 144/A date 04/22/2026 date of the amended filing entry

Key Terms

Form 144/A, compensation (bonus), resale notice

3 terms

Form 144/A regulatory

"submitted an amended Form 144/A reporting a proposed resale"

compensation (bonus) financial

"lists the shares as issued for <b>compensation</b> (a <b>bonus</b>)"

resale notice regulatory

"a proposed resale of <b>100,000 common shares</b> by <b>Daniel Apel</b>"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ARWR's Form 144/A filing mean for investors?

It notifies the market that an insider intends to offer shares for resale. The filing lists 100,000 common shares by Daniel Apel, dated 04/22/2026, tied to a bonus granted on 04/15/2025.

Who is selling the shares in the ARWR Form 144/A?

The filing identifies Daniel Apel as the holder associated with the proposed resale. The record classifies the shares as issued for compensation (bonus) with the grant date shown as 04/15/2025.

How many ARWR shares are listed in the amended Form 144/A?

The amendment lists 100,000 common shares as the amount proposed for resale. The Form 144/A entry shows the filing date as 04/22/2026 and links the shares to a compensation award.

Does the Form 144/A confirm the shares have been sold?

No. Form 144/A is a notice of proposed resale under securities rules. The excerpt reports intent to sell 100,000 shares but does not confirm execution, price, or settlement details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 04:46 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK	0002081169
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001628280-26-026634
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer	Arrowhead Pharmaceuticals Inc.
SEC File Number
Address of Issuer	177 E. Colorado Blvd Suite 700 Pasadena CALIFORNIA 91105
Phone	626-3043400
Name of Person for Whose Account the Securities are To Be Sold	Daniel Apel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 75 Rockefeller Plaza New York NY 10019	13095	934206.16	140032190	04/22/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/15/2025	Bonus	Daniel Apel			100000	04/22/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report

144/A: Remarks and Signature

Remarks	Form 144 being amended to add in 10b5-1 adoption date. Original date of notice 04/22/2026.
Date of Notice	05/19/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/16/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daniel Apel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)